Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: V08DA

EchoGen(dodecafluoropentane)

Echocardiography

Marketing Authorisation Holder: Sonus Pharmaceuticals Ltd.

EMA Authorisation: 17/07/1998

INN: dodecafluoropentane

Indication

EchoGen is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular border delineation with resulting improvement in wall motion visualisation. EchoGen should only be used in patients where the study without contrast enhancement is inconclusive.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about EchoGen — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.